gamma-aminobutyric acid has been researched along with Cafe-au-Lait Spots with Pulmonic Stenosis in 11 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We found that patients with neurofibromatosis type 1 have significantly lower γ-aminobutyric acid levels than control subjects, and that neurofibromatosis type 1 mutation type significantly predicted cortical γ-aminobutyric acid." | 1.39 | GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact. ( Bernardino, I; Castelo-Branco, M; Cunha, G; Edden, RA; Guimarães, P; Rebola, J; Ribeiro, MJ; Silva, E; Violante, IR, 2013) |
| "Neurofibromatosis type 1 is one of the most common monogenic disorders causing cognitive deficits for which studies on a mouse model (Nfl(+/-)) proposed increased γ-aminobutyric acid-mediated inhibitory neurotransmission as the neural mechanism underlying these deficits." | 1.39 | GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact. ( Bernardino, I; Castelo-Branco, M; Cunha, G; Edden, RA; Guimarães, P; Rebola, J; Ribeiro, MJ; Silva, E; Violante, IR, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Lacroix, A | 1 |
| Proteau-Lemieux, M | 1 |
| Côté, S | 1 |
| Near, J | 1 |
| Hui, SCN | 1 |
| Edden, RAE | 1 |
| Lippé, S | 1 |
| Çaku, A | 1 |
| Corbin, F | 1 |
| Lepage, JF | 1 |
| Garg, S | 1 |
| Williams, S | 1 |
| Jung, J | 1 |
| Pobric, G | 1 |
| Nandi, T | 1 |
| Lim, B | 1 |
| Vassallo, G | 1 |
| Green, J | 1 |
| Evans, DG | 1 |
| Stagg, CJ | 1 |
| Parkes, LM | 1 |
| Stivaros, S | 1 |
| Violante, IR | 3 |
| Ribeiro, MJ | 2 |
| Edden, RA | 2 |
| Guimarães, P | 1 |
| Bernardino, I | 3 |
| Rebola, J | 2 |
| Cunha, G | 1 |
| Silva, E | 1 |
| Castelo-Branco, M | 3 |
| Zimerman, M | 1 |
| Wessel, MJ | 1 |
| Timmermann, JE | 1 |
| Granström, S | 1 |
| Gerloff, C | 1 |
| Mautner, VF | 1 |
| Hummel, FC | 1 |
| Patricio, M | 1 |
| Abrunhosa, AJ | 1 |
| Ferreira, N | 1 |
| Cui, Y | 1 |
| Costa, RM | 2 |
| Murphy, GG | 2 |
| Elgersma, Y | 1 |
| Zhu, Y | 1 |
| Gutmann, DH | 1 |
| Parada, LF | 1 |
| Mody, I | 1 |
| Silva, AJ | 3 |
| Shilyansky, C | 1 |
| Karlsgodt, KH | 1 |
| Cummings, DM | 1 |
| Sidiropoulou, K | 1 |
| Hardt, M | 1 |
| James, AS | 1 |
| Ehninger, D | 1 |
| Bearden, CE | 1 |
| Poirazi, P | 1 |
| Jentsch, JD | 1 |
| Cannon, TD | 1 |
| Levine, MS | 1 |
| Pérez Villena, A | 1 |
| Duat Rodríguez, A | 1 |
| García Peñas, JJ | 1 |
| López Pino, MA | 1 |
| Das, UN | 1 |
| Federov, NB | 1 |
| Kogan, JH | 1 |
| Stern, J | 1 |
| Ohno, M | 1 |
| Kucherlapati, R | 1 |
| Jacks, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Linking Inhibition From Molecular to Systems and Cognitive Levels: a Preclinical and Clinical Approach in Autism Spectrum Disorders and Neurofibromatosis.[NCT03826940] | 16 participants (Actual) | Interventional | 2019-02-19 | Completed | |||
| Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)[NCT00352599] | Phase 1 | 44 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gamma-aminobutyric acid and Cafe-au-Lait Spots with Pulmonic Stenosis
| Article | Year |
|---|---|
Can memory be improved? A discussion on the role of ras, GABA, acetylcholine, NO, insulin, TNF-alpha, and long-chain polyunsaturated fatty acids in memory formation and consolidation.
Topics: Acetylcholine; Animals; Brain; Cognition; Fatty Acids, Unsaturated; gamma-Aminobutyric Acid; Humans; | 2003 |
1 trial available for gamma-aminobutyric acid and Cafe-au-Lait Spots with Pulmonic Stenosis
| Article | Year |
|---|---|
Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Neurofibromatosis 1; Prefrontal Cortex; Single-Blind Method; | 2022 |
9 other studies available for gamma-aminobutyric acid and Cafe-au-Lait Spots with Pulmonic Stenosis
| Article | Year |
|---|---|
Multimodal assessment of the GABA system in patients with fragile-X syndrome and neurofibromatosis of type 1.
Topics: Fragile X Syndrome; gamma-Aminobutyric Acid; Humans; Motor Cortex; Neural Inhibition; Neurofibromato | 2022 |
GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact.
Topics: Adolescent; Brain Chemistry; Child; Female; gamma-Aminobutyric Acid; Genotype; Humans; Magnetic Reso | 2013 |
Abnormal relationship between GABA, neurophysiology and impulsive behavior in neurofibromatosis type 1.
Topics: Adolescent; Attention; Brain; Child; Electroencephalography; Executive Function; Female; gamma-Amino | 2015 |
Impairment of Procedural Learning and Motor Intracortical Inhibition in Neurofibromatosis Type 1 Patients.
Topics: Adult; Female; gamma-Aminobutyric Acid; Humans; Learning; Long-Term Potentiation; Male; Middle Aged; | 2015 |
GABA deficiency in NF1: A multimodal [11C]-flumazenil and spectroscopy study.
Topics: Adult; Brain; Case-Control Studies; Cross-Sectional Studies; Female; Flumazenil; GABA Modulators; ga | 2016 |
Neurofibromin regulation of ERK signaling modulates GABA release and learning.
Topics: Animals; Extracellular Signal-Regulated MAP Kinases; Female; gamma-Aminobutyric Acid; Genes, Neurofi | 2008 |
Neurofibromin regulates corticostriatal inhibitory networks during working memory performance.
Topics: Animals; Behavior, Animal; Computer Simulation; Excitatory Postsynaptic Potentials; Female; gamma-Am | 2010 |
Plexiform neurofibroma in an 8 year-old patient.
Topics: Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2013 |
Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.
Topics: Animals; Disease Models, Animal; gamma-Aminobutyric Acid; Genes, ras; Hippocampus; In Vitro Techniqu | 2002 |